Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-07-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
发行人及保荐机构关于上海美迪西生物医药股份有限公司向特定对象发行股票申请文件的审核问询函之回复报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to an inquiry letter from the Shanghai Stock Exchange regarding a company's application for a specific share issuance to targeted investors. It discusses in depth the company's fundraising project, investment plans, market analysis, technical and personnel capabilities, and competitive positioning. The content focuses on the company's capital raising activities, specifically the issuance of shares to targeted investors and the use of the raised funds for expansion projects. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a comprehensive response related to a capital raising filing, which aligns with the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the appropriate classification is CAP with high confidence.
2022-07-05 Chinese
北京金诚同达律师事务所关于上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票之补充法律意见书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a specific issuance of A shares by Shanghai Medicilon Inc. in 2022. It includes extensive legal verification and compliance checks related to the issuance, such as land use rights, environmental approvals, legal compliance of controlling shareholders and management, and regulatory approvals. The document references the issuance process, regulatory inquiries, and legal opinions on the issuance's legitimacy and compliance with securities laws. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital raising event. This fits the category of Capital/Financing Update (CAP), as it pertains to the issuance of shares to specific investors and the legal due diligence around that issuance.
2022-07-05 Chinese
立信会计师事务所（特殊普通合伙）关于上海美迪西生物医药股份有限公司2022年度向特定对象发行股票的财务报表及审计报告
Regulatory Filings
2022-07-05 Chinese
北京金诚同达律师事务所关于上海美迪西生物医药股份有限公司2022年度向特定对象发行股票之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding Shanghai Medicilon Inc.'s 2022 issuance of A shares to specific investors. It includes extensive legal analysis, approvals, authorizations, company establishment details, shareholder information, compliance with securities laws, and regulatory requirements. The document references audit reports, shareholder meetings, board resolutions, and regulatory filings related to the share issuance. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. Instead, it is a comprehensive legal opinion supporting a capital raising event through a specific share issuance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-07-05 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票变更签字会计师的专项说明
Capital/Financing Update Classification · 95% confidence The document is a specific announcement regarding the change of signing auditors for a particular issuance of A shares by Shanghai Medicilon Inc. It details the change of the signing accountants, their qualifications, and assurances about the validity of previously signed documents. The document is short (975 characters) and focuses on a procedural update related to a capital issuance process, not the issuance itself or a full financial report. It does not contain financial statements or detailed financial data. This fits best under Capital/Financing Update (CAP) as it relates to a financing activity update (change in signing auditors for a share issuance).
2022-07-05 Chinese
美迪西：关于向特定对象发行股票申请文件的审核问询函及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shanghai Medicilon Inc. regarding updates to application documents for a private placement of shares (向特定对象发行股票). It references receipt of an inquiry letter from the Shanghai Stock Exchange and updates to the prospectus and related application documents. The text mentions that the issuance requires approval from the China Securities Regulatory Commission and that the company will disclose further information as the process progresses. The document is short (883 characters) and primarily serves as an announcement about the status and updates of the share issuance application, not the actual detailed financing report or prospectus itself. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes.
2022-07-05 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.